Thiazolidinediones (TZDs) are a new class of insulin sensitizers with the potential to treat Type II (non-insulin-dependent) diabetes mellitus [1, 2] . It has been shown in diabetic humans as well as in rodent models of diabetes that TZDs considerably improve insulin sensitivity by stimulating glucose uptake in peripheral tissues and by inhibiting hepatic gluconeogenesis [3±6]. It is thought that TZDs mainly act by binding to the nuclear transcription factor peroxisome proliferator activated receptor gamma (PPARg) and thereby modify the expression of various genes implicated in glucose and lipid metabolism [7] . PPARg is expressed very early during adipocyte differentiation. Ectopic expression of PPARg in fibroblasts is suffi- Diabetologia (1999) Abstract Aims/hypothesis. Thiazolidinediones, a new class of insulin sensitizers, up-regulate the expression of uncoupling protein 2 in rodent adipocytes. It is not known, however, whether thiazolidinediones influence uncoupling protein 2 expression in human adipocytes. We therefore investigated the effect of these drugs on uncoupling protein 2 expression in the recently immortalized human PAZ6 adipocyte cell line. Methods. Immortalized human PAZ6 preadipocytes were differentiated into adipocytes in the presence or absence of thiazolidinediones. The effect of the drugs on uncoupling protein 2 expression and adipocyte differentiation was measured by reverse transcription-polymerase chain reaction of mRNA of uncoupling protein 2 and of five adipocyte differentiation markers. Results. When cells were differentiated 15 days in the presence of thiazolidinediones, uncoupling protein 2 expression was 2.1-fold higher than in the absence of the drugs. The expression of five adipocyte differentiation markers was, however, also increased by thiazolidinediones. Short-term incubation for 4 and 24 h with thiazolidinediones increased uncoupling protein 2 expression 1.35-fold and 2.3-fold, respectively. The expression of adipocyte markers studied in parallel was also augmented. Conclusion/interpretation. Thiazolidinediones rapidly increase the expression of uncoupling protein 2 in human PAZ6 adipocytes but the increase of uncoupling protein 2 expression is always associated with an augmentation of the expression of all adipocyte markers studied in parallel. This indicates that the effect of thiazolidinediones on uncoupling protein 2 mRNA reflects a general increase in adipocyte differentiation rather than a specific augmentation of uncoupling protein 2 gene expression. [Diabetologia (1999) 42: 527±533] 
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Thiazolidinediones also increase the potential for thermogenic energy expenditure in rodents [11] which could be associated with the capacity to up-regulate the expression of uncoupling proteins. Uncoupling proteins are proton conducting proteins of the inner mitochondrial membrane that uncouple the respiratory chain reactions from ATP synthesis [12±17]. These proteins therefore potentially constitute targets for anti-obesity treatments aimed at burning excess fat. Uncoupling protein 1 is restricted to brown adipose tissue, which is lacking in adult humans. Uncoupling protein 2 is expressed in numerous tissues of rodents and humans, including muscle and fat [15, 18, 19] . Recent experiments point to UCP2 having a role in uptake of lipids as fuel substrates rather than in diet-induced thermogenesis [20] . For example, UCP2 is up-regulated in muscle tissue of starving rats and also in animals fed on a high-fat diet compared with animals fed an isocaloric low-fat diet. A positive correlation has been shown between BMI and UCP2 expression in humans [21] . On the other hand, in two rodent models of obesity, no correlation between body weight and UCP2 expression has been observed [22, 23] ). In addition, no linkage between UCP2 polymorphisms and Type II diabetes has been found [24±26] .
In rodent adipocytes and muscle cell lines, thiazolidinediones can potently upregulate UCP2 but data on modulation of UCP2 expression by TZDs in human adipocytes are not available. We have therefore investigated the effect of thiazolidinediones on UCP2 expression in PAZ6 cells, a recently described immortalized human adipocyte cell line [27] . . Naphthiazo was a kind gift from Dr. J. Duhault (IRIS, France). Pioglitazone was synthesized according to published protocols [28] . All other chemicals were purchased from Sigma (Saint Quentin, Fallavier, France) if not otherwise stated and were of the highest purity grade available.
Materials and methods
Cell culture of PAZ6 cell line. Throughout this study, immortalized PAZ6 cells [27] have been used. Preadipocytes were cultivated in F-12-DMEM-Ham's medium (1:1 vol/vol, designated as F/D medium) supplemented with 10 % FCS and 15 mmol/l HEPES. For differentiation, confluent PAZ6 preadipocytes were cultivated for 2 weeks in F/D medium supplemented with 5 % FCS, 0.1 mmol/l dexamethasone, 850 nmol/l insulin, 1 nmol/l triiodothyronine and 1 mmol/l naphthiazo or pioglitazone for 2 weeks. This medium is designated as differentiation medium. The differentiation medium was changed every other day. During the first 4 days of differentiation, 3-isobutyl-1-methyl-xanthine was added (IBMX, 0.25 mmol/l). In some experiments, TZDs were removed during the second week of differentiation and re-added for 4 or 24 h before RNA extraction.
Measurement of intracellular triglyceride content. Adipose conversion was measured by staining intracytoplasmic lipids with Oil red O using a previously published protocol [29] .
RNA isolation. Total RNA was extracted from PAZ6 cells using the TRIZOL reagent (Gibco Life Sciences, Cergy, Pontoise, France). From this RNA 20 mg were digested with 6 U RNase-free DNase I (RQ1 DNase, Promega, Lyon, France) in 40 mmol/l TRIS-HCl, pH 7.9, 10 mmol/l NaCl, 6 mmol/l MgCl 2 and 2 U/ml RNase inhibitor (RNaseOUT, Gibco Life Sciences). The RNA was extracted with phenol/chloroform, precipitated with ethanol, dried and resuspended in water. Concentrations of RNA were determined photometrically and integrity of total RNA was assessed by agarose electrophoresis. The samples were stored at ±80°C.
Generation of synthetic RNAs for competitive reverse transcription RT-PCR. Synthetic RNA competitors were designed to be amplified in RT-PCR with the same primers that were used for the RT-PCR of UCP2 or aP2 mRNAs, but giving PCR-products differing in size from the endogenous reverse transcribed mRNAs. These synthetic RNA competitors for quantification of UCP2 and aP2 mRNAs were generated by RT-PCR of PAZ6 RNA using composite primers as described [30] and the Ribomax RNA-synthesis kit (Promega). Sense composite primers specific for the UCP2 or aP2 gene contained the T7-RNA-polymerase universal promotor at their 5 ¢ end allowing for transcription of the PCR-products into RNA. Antisense composite primers contained at their 5 ¢ moiety the UCP2 or aP2 antisense primers described in the paragraph ªRT-PCRº, but annealed with their 3 ¢ moiety more upstream.
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RT-PCR. cDNA was synthesized from 200 ng DNA-free total RNA using Moloney murine leukemia virus reverse transcriptase (Superscript II Plus, Gibco Life Sciences) according to the manufacturer's protocol. For quantitative competitive RT-PCR analysis of gene expression, PAZ6 total RNA was reverse transcribed in the presence of known amounts of syn-thetic competitor RNA. Controls without reverse transcriptase were done in order to exclude DNA contamination. We amplified 50±400 ng of reverse-transcribed RNA with 1.5 U Taq Polymerase (Gibco Life Sciences) in 50 ml containing 20 mmol/l TRIS-HCl, pH 8.0, 50 mmol/l KCl, 1,5 mmol/l MgCl 2 , 250 mmol/l dNTP and 250 mmol/l of gene-specific sense-primers and antisense-primers in a temperature cycler (GeneAmp PCR System 9600, Perkin-Elmer Cetus, Courtaboeuf, France). The PCR-products were made visible on 2 % agarose gels by ethidium bromide staining. The PCRband intensities were analysed by densitometric scanning. For all semi-quantitative RT-PCRs, analysis of mRNA expression was carried out during the exponential phase of the amplification. The exponential phase of each RT-PCR was determined by titrations of cycle numbers and quantities of total RNA.
Primers for the following mRNAs were designed with the program Oligo4 using the following Genbank entries: Statistical analysis. Data were analysed using Student's t test for unpaired data.
Results
Differentiation of PAZ6 cells and expression of Uncoupling Protein 2. In preliminary experiments, we determined that a 2-week period of exposure to a standard differentiation medium was optimal for differentiation of the PAZ6 cells, as judged by expression of adipocyte markers (not shown). Here we assessed the extent of differentiation of these cells in more detail by semi-quantitative RT-PCR of the mRNAs of the adipocyte markers lipoprotein lipase (LPL), b 3 -adrenergic receptor (b 3 -AR), hormone sensitive lipase (HSL), human fatty acid binding protein (aP2), and peroxisome proliferator activated receptor g (PPARg). Total RNAs were isolated from confluent preadipocytes (t = 0 of differentiation) and after 1 and 2 weeks of differentiation. The expression of these genes increases as the PAZ6 cells acquire the phenotype of mature adipocytes (Fig. 1) .
Recently, UCP2, a homologue of the brown adipocyte-specific uncoupling protein 1 (UCP1), has been cloned [15, 16] . The expression pattern of UCP2 in human adipocytes during differentiation is not known. We therefore examined the expression of UCP2 in differentiating PAZ6 cells by semi-quantitative RT-PCR. We found that UCP2 mRNA is already present in preadipocytes at confluence (beginning of the differentiation protocol) (Fig. 1) . After 1 week of differentiation, the mRNA expression rose twofold and were 2.7-fold higher at day 14 of differentiation than at day 0, showing that, as described for rodent adipocytes [31] , UCP2 mRNA expression increases during differentiation of human adipocytes.
Effect of thiazolidinediones on UCP2 expression and PAZ6 differentiation. In a first set of experiments, we investigated the long-term effect of TZDs on UCP2 expression in PAZ6 cells. Simultaneously, we examined how these drugs influence the differentiation state of the cells. We assessed the long-term effect of two different TZDs, naphthiazo and pioglitazone, on UCP2 expression in human PAZ6 cells (Fig. 2 a) . Compared with cell differentiated in a me- Fig. 1 . Expression of adipocyte markers during differentiation of PAZ6 cells. Cells were differentiated as described in Materials and methods. For each point in time, semi-quantitative RT-PCR was carried out in duplicate. PCR products were made visible on agarose gels by ethidium bromide staining. As a control, the signals for cyclophilin expression are also shown. The results are representative of four independent experiments done in duplicate dium lacking TZDs, UCP2 expression was about 2.1-fold higher in adipocytes differentiated in the presence of 1 mmol/l TZD. Examination of the mRNA expressions of the other genes studied shows that both TZDs have also a profound effect on the differentiation of the cells. Cells incubated for 2 weeks with a differentiation medium lacking TZDs barely express aP2 and LPL mRNAs, and b 3 -AR and HSL are expressed at low levels compared with cells that were exposed for 2 weeks to naphthiazo or pioglitazone. The influence of TZDs on adipocyte differentiation was also measured by staining of intracellular triglycerides, which accumulate during differentiation. We plotted triglyceride content of PAZ6 cells differentiated in the absence or presence of naphthiazo compared with the time of differentiation (Fig. 2 b) . After 15 days of differentiation, lipid accumulation was about twofold higher in cells differentiated in the presence of naphthiazo. Altogether, these results show that long-term incubation of PAZ6 cells with TZDs increases UCP2 expression but also the differentiation state of the cells as judged by triglyceride content and the expression of differentiation markers. It is thus not possible to conclude from this experiment that TZDs specifically alter UCP2 expression.
To investigate the role of TZDs in UCP2 expression in adipocytes differentiated to a maximum, cells were differentiated for 2 weeks in the presence of TZDs. We replaced the differentiation medium by the same medium but lacking TZD 24 h before RNA extraction. Removal of TZDs considerably reduced aP2 and UCP2 expression, but also that of all the other adipocyte markers we tested (Fig. 3) . Again, it was not possible to dissociate the effect on UCP2 expression from the effect on the differentiation state of the cells. Apparently, even terminally differentiated PAZ6 cells need the continous presence of TZDs to maintain a maximum differentiated phenotype.
We next investigated UCP2 expression in PAZ6 cells upon short-term exposure to TZDs. Cells were differentiated for the first week in the presence of either naphthiazo or pioglitazone. In the second week, cells were differentiated in the same differentiation medium but lacking TZDs. Cells were then incubated or not with TZDs for 24 h. Treatment with naphthiazo for 24 h increased UCP2 expression by a Fig. 3 . Expression of adipocyte-associated genes after removal of naphthiazo (NTZ). PAZ6 cells were differentiated with the differentiation cocktail containing NTZ as described in Materials and methods. NTZ was removed from the medium 24 h before RNA extraction (Fig. 4) . Incubation of PAZ6 cells with TZDs for 24 h increased the expression of all the adipocyte differentiation markers we tested (Fig. 5) .
Finally, to determine whether a shorter stimulation would show kinetic differences between UCP2 expression and the expression of other markers, we repeated the experiment shown in Figure 5 , reducing the time of incubation with TZDs to 4 h. Quantitative RT-PCR measurements carried out as described in Figure 3 showed that 4-h incubation with naphthiazo increased UCP2 expression 1.350 ± 0.014-fold (n = 3, p < 0.003). The expression of all markers studied are depicted (Fig. 6) . As in Figure 4 , all markers with the exception of PPARg, were augmented after 4 h of TZD treatment.
These results suggest that even for very short incubations, the effect of TZDs on UCP2 expression cannot be distinguished from the effect of these drugs on other adipocyte differentiation markers. The augmentation of UCP2 by TZDs appears to be a mere consequence of the differentiation promoting action of these drugs.
Discussion
In this study, we have reported the expression of several adipocyte markers in human adipocytes during differentiation. Virtually no expression is detectable for the b 3 -AR, HSL and aP2 genes in confluent PAZ6 preadipocytes. These proteins are involved in lipid metabolism or storage or both. Adipocytes acquire the enzymes for lipid storage and mobilization, such as HSL, b 3 -AR and aP2, late during the differentiation process [32] . In particular, b 3 -AR and HSL are considered to be late markers of adipocyte differentiation [33, 32] whereas LPL is an exception and is thought to be an early marker expressed at confluence in rodent adipocytes [34] . We observed that expression of LPL was very weak in confluent preadipocytes and continued to augment during the whole differentiation process. This difference in the expression pattern of LPL between PAZ6 cells and rodent cells could be due to species-specific differences. In agreement with our results, LPL activity measured during differentiation in primary cultures of human adipocytes has been shown to reach its maximum only after 2 weeks of differentiation [35] .
We further showed that PPARg is already expressed in confluent preadipocytes. As shown in rodents [36] , PPARg is therefore an early differentiation marker in human PAZ6 adipocytes. This is in line with its role as a master transcription factor regulating adipocyte differentiation. Its increase during 2 weeks of differentiation (1.5-fold) is not as pronounced as for aP2, HSL, b 3 -AR or LPL.
The effect of TZDs on rodent adipocyte differentiation has been studied extensively. In human adipocytes the effect of troglitazone on adipocyte differentiation has been quantified by measuring glycerol-3-phophate dehydrogenase activity [37] . There is, however, no detailed analysis of the effect of these drugs on the expression of differentiation markers in human adipocytes. We have reported here the effect of TZDs on the expression of several genes in human PAZ6 adipocytes. In line with previous reports on rodent adipocytes [38, 7] , we show that TZDs strongly increase the expression of several adipocyte markers.
Two studies describe the stimulation of UCP2 expression by TZDs and PPARg activators in rodent cell lines but the possibility that these effects could be due to a general increase in the differentiation state of the cells has not been examined. Murine adipocytes have been incubated at confluence for various times with TZDs but the expression of differentiation markers was not measured [39] . An increase of UCP2 expression in differentiated Ob1771 cells during shortterm treatment with troglitazone, which is accompanied by an increase in the murine aP2 gene expression has been shown [31] . Since this latter gene is, however, known to possess a peroxisome proliferator responsive element (PPRE) and to be rapidly induced by TZDs, it cannot be determined from this study whether short-term incubation with TZDs specifically upregulates UCP2 and aP2 expression or whether it affects the general differentiation state of the cell.
In this study, we also assessed the influence of short-term incubation with TZDs on the expression of the UCP2 gene. After 4-or 24-h exposure of PAZ6 cells to TZDs, the TZD-induced increase in UCP2 expression was accompanied by a rise in most of the differentiation markers studied. The genes for LPL and aP2 both possess a functional PPRE in their promoters [40, 41] and have been shown to be directly activated by liganded PPARg. In contrast, the promoters of the HSL and b 3 -AR genes have not so far been reported to contain a PPRE [42, 43] . The up-regulation of the mRNAs for b 3 -AR and HSL within 4 h of TZDs exposure, points to the possibility that even indirect consequences of TZDs action occur rapidly.
In conclusion, we have shown that TZDs stimulate UCP2 expression in human adipocytes but that TZDs also rapidly augment the expression of various adipocyte markers. The up-regulation of UCP2 mRNA could be the result of an increased differentiation of the cell rather than a specific effect on UCP2 gene expression. 
